| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Diego A Cifuente, Mariana G Vallejo, Maria G Ortega, José L Cabrera, Víctor S Martín, Carlos E Tonn, Alicia M Agnese, Carlos E Ardana. Mass spectrometry studies of lycodine-type Lycopodium alkaloids: sauroxine and N-demethylsauroxine. Rapid communications in mass spectrometry : RCM. vol 28. issue 24. 2015-06-23. PMID:25380490. |
it is known that drugs that inhibit acetylcholinesterase can be used to treat the early stages of alzheimer's disease. |
2015-06-23 |
2023-08-13 |
Not clear |
| Jacques Touchon, Jean Lachaine, Catherine Beauchemin, Anna Granghaud, Benoit Rive, Sébastien Binea. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. The European journal of health economics : HEPAC : health economics in prevention and care. vol 15. issue 8. 2015-06-22. PMID:23928827. |
the impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with alzheimer's disease to nursing homes: cost-effectiveness analysis in france. |
2015-06-22 |
2023-08-12 |
Not clear |
| Patrizia Russo, Alessandra Del Bufalo, Alessandra Frustaci, Massimo Fini, Alfredo Cesari. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials. Current pharmaceutical design. vol 20. issue 38. 2015-06-22. PMID:24641224. |
beyond acetylcholinesterase inhibitors for treating alzheimer's disease: α7-nachr agonists in human clinical trials. |
2015-06-22 |
2023-08-12 |
human |
| Tadashi Watabe, Sadahiro Naka, Hayato Ikeda, Genki Horitsugi, Yasukazu Kanai, Kayako Isohashi, Mana Ishibashi, Hiroki Kato, Eku Shimosegawa, Hiroshi Watabe, Jun Hatazaw. Distribution of intravenously administered acetylcholinesterase inhibitor and acetylcholinesterase activity in the adrenal gland: 11C-donepezil PET study in the normal rat. PloS one. vol 9. issue 9. 2015-06-22. PMID:25225806. |
acetylcholinesterase (ache) inhibitors have been used for patients with alzheimer's disease. |
2015-06-22 |
2023-08-13 |
rat |
| C W Ritchie, J Bajwa, G Coleman, K Hope, R W Jones, M Lawton, M Marven, P Passmor. Souvenaid®: a new approach to management of early Alzheimer's disease. The journal of nutrition, health & aging. vol 18. issue 3. 2015-06-18. PMID:24626757. |
two randomised, double-blind, controlled trials (duration 12 and 24 weeks) in patients with mild alzheimer's disease untreated with acetylcholinesterase inhibitors and/or memantine have demonstrated that souvenaid® is well tolerated and improves episodic memory performance. |
2015-06-18 |
2023-08-12 |
human |
| Michela Rosini, Elena Simoni, Anna Minarini, Carlo Melchiorr. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochemical research. vol 39. issue 10. 2015-06-08. PMID:24493627. |
multi-target design strategies in the context of alzheimer's disease: acetylcholinesterase inhibition and nmda receptor antagonism as the driving forces. |
2015-06-08 |
2023-08-12 |
Not clear |
| Andreas G Franke, Christiana Bagusat, Sebastian Rust, Alice Engel, Klaus Lie. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. European archives of psychiatry and clinical neuroscience. vol 264 Suppl 1. 2015-06-08. PMID:25214391. |
attentin(®) or adderall(®)), to treat sleep disorders such as modafinil or to treat alzheimer's disease such as acetylcholinesterase inhibitors; (3) illicit drugs such as illicit amph, e.g. |
2015-06-08 |
2023-08-13 |
human |
| Soichiro Shimizu, Hidekazu Kanetaka, Daisuke Hirose, Hirohumi Sakurai, Haruo Hany. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dementia and geriatric cognitive disorders extra. vol 5. issue 1. 2015-05-22. PMID:25999980. |
differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with alzheimer's disease: a 12-month, randomized, and open-label trial. |
2015-05-22 |
2023-08-13 |
Not clear |
| Akiko Ishiwata, Sunao Mizumura, Masahiro Mishina, Mineo Yamazaki, Yasuo Katayam. The potentially protective effect of donepezil in Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 38. issue 3-4. 2015-05-12. PMID:24732387. |
donepezil is an acetylcholinesterase inhibitor used to treat alzheimer's disease (ad). |
2015-05-12 |
2023-08-13 |
Not clear |
| M R Islam, S Moriguchi, H Tagashira, K Fukunag. Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice. Neuroscience. vol 272. 2015-05-11. PMID:24797332. |
rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (ache) and butylcholinesterase (buche) used to treat mild to moderate dementia in alzheimer's disease (ad) patients. |
2015-05-11 |
2023-08-13 |
mouse |
| Dawei Zhang, Yue Zho. The protective effects of Donepezil (DP) against cartilage matrix destruction induced by TNF-α. Biochemical and biophysical research communications. vol 454. issue 1. 2015-05-01. PMID:25450366. |
donepezil (dp), a potent and selective acetylcholinesterase inhibitor, is a medication approved by the us food and drug administration and used in the alleviation of dementia in alzheimer's disease (ad). |
2015-05-01 |
2023-08-13 |
Not clear |
| Zi-Qiang Sha. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. International journal of clinical and experimental medicine. vol 8. issue 2. 2015-05-01. PMID:25932260. |
combined use of memantine and acetylcholinesterase inhibitors (acheis) has shown improved outcomes in patients with alzheimer's disease (ad). |
2015-05-01 |
2023-08-13 |
Not clear |
| Christina E Turi, Katarina E Axwik, Anderson Smith, A Maxwell P Jones, Praveen K Saxena, Susan J Murc. Galanthamine, an anticholinesterase drug, effects plant growth and development in Artemisia tridentate Nutt. via modulation of auxin and neutrotransmitter signaling. Plant signaling & behavior. vol 9. issue 3. 2015-04-21. PMID:24690897. |
galanthamine is a naturally occurring acetylcholinesterase (ache) inhibitor that has been well established as a drug for treatment of mild to moderate alzheimer disease, but the role of the compound in plant metabolism is not known. |
2015-04-21 |
2023-08-13 |
Not clear |
| Houria Berhail Boudouda, Assia Zeghib, Anastazia Karioti, Anna Rita Bilia, Mehmet Öztürk, Mahjoub Aouni, Ahmed Kabouche, Zahia Kabouch. Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae). Pakistan journal of pharmaceutical sciences. vol 28. issue 1. 2015-04-20. PMID:25553679. |
since there is a relationship between antioxidants and cholinesterase enzyme inhibitors, we used two methods to determine the in vitro anti-cholinesterase activity by the use of the basic enzymes that occur in causing alzheimer's disease: acetylcholinesterase (ache) and butyrylcholinesterase (bche). |
2015-04-20 |
2023-08-13 |
human |
| Giulia Paroni, Davide Seripa, Andrea Fontana, Grazia D'Onofrio, Carolina Gravina, Maria Urbano, Leandro Cascavilla, Fabio Pellegrini, Antonio Greco, Alberto Pilott. FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. Clinical interventions in aging. vol 9. 2015-04-07. PMID:25364236. |
foxo1 locus and acetylcholinesterase inhibitors in elderly patients with alzheimer's disease. |
2015-04-07 |
2023-08-13 |
Not clear |
| Giulia Paroni, Davide Seripa, Andrea Fontana, Grazia D'Onofrio, Carolina Gravina, Maria Urbano, Leandro Cascavilla, Fabio Pellegrini, Antonio Greco, Alberto Pilott. FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. Clinical interventions in aging. vol 9. 2015-04-07. PMID:25364236. |
acetylcholinesterase inhibitors (acheis) may reduce the oxidative stress in brain of alzheimer's disease (ad) patients. |
2015-04-07 |
2023-08-13 |
Not clear |
| María-Letizia Campanari, María-Salud García-Ayllón, Lidia Blazquez-Llorca, Wilson K W Luk, Karl Tsim, Javier Sáez-Valer. Acetylcholinesterase protein level is preserved in the Alzheimer's brain. Journal of molecular neuroscience : MN. vol 53. issue 3. 2015-04-06. PMID:24318838. |
acetylcholinesterase protein level is preserved in the alzheimer's brain. |
2015-04-06 |
2023-08-12 |
Not clear |
| María-Letizia Campanari, María-Salud García-Ayllón, Lidia Blazquez-Llorca, Wilson K W Luk, Karl Tsim, Javier Sáez-Valer. Acetylcholinesterase protein level is preserved in the Alzheimer's brain. Journal of molecular neuroscience : MN. vol 53. issue 3. 2015-04-06. PMID:24318838. |
acetylcholinesterase (ache) is a key enzyme in the cholinergic nervous system and is one of the most studied proteins in the field of alzheimer's disease (ad). |
2015-04-06 |
2023-08-12 |
Not clear |
| Rahul P Modh, Sivakumar Prasanth Kumar, Yogesh T Jasrai, Kishor H Chikhali. Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors. Archiv der Pharmazie. vol 346. issue 11. 2015-04-06. PMID:24591157. |
acetylcholinesterase (ache) is an important drug target for the treatment of alzheimer's disease. |
2015-04-06 |
2023-08-12 |
human |
| Qi Sun, Da-Yong Peng, Sheng-Gang Yang, Xiao-Lei Zhu, Wen-Chao Yang, Guang-Fu Yan. Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase. Bioorganic & medicinal chemistry. vol 22. issue 17. 2015-04-06. PMID:25088549. |
exploring small-molecule acetylcholinesterase (ache) inhibitors to slow the breakdown of acetylcholine (ach) represents the mainstream direction for alzheimer's disease (ad) therapy. |
2015-04-06 |
2023-08-13 |
human |